When mentioning “breast cancer” in a story about my college experience is not allowed, I considered alternatives to the medical term that describes my situation best.
My alma mater was collecting stories about our college experiences, so I decided to submit. Because my brother’s cancer experience was the centerpiece of my college experience, I had to write about him. With a nod to lifelong learning, I thought I would briefly mention my own cancer in this sentence: “I checked a book out of the library to try to understand my brother’s cancer, although it would take further study and my own journey with invasive breast cancer as an adult to understand cancer more thoroughly.”
After pasting my college story into a submission form, I was surprised by a flag for profanity: “Profanity detected: 1.” Profanity? I perused the story I had printed to proof and was stymied. I know I am not as young as I used to be. Was there some new profane term I did not know of?
Glancing at the submission form on my laptop, I noticed that my work had been done for me. There, now in bold red letters, was the word flagged as profanity: “breast.” Well, I thought there is a first time for everything, including an automated editor that can't recognize a medically appropriate compound noun (“breast cancer”). What human or bot had programmed the submission manager? With the word “breast” flagged, I could not submit my story.
Should I cut the word “breast” out, I pondered, and just mention cancer? Should I delete all mention of cancer? Maybe I should only talk about how my professors helped me to grow intellectually. Maybe I should just observe that my college experience had a positive influence on a shy girl who blossomed into a more confident young woman. But I really wanted to write from the heart.
Procrastinating a decision about how to revise my alumni story, I decided to play a word game by testing the automated editor. These words were rejected by the program reading my words: hell, breast, testicle, nipple. These words passed muster: testicular cancer, testes, mammary gland, bosom. The automated editor would allow “testicular cancer” although not “testicle.” It would not allow “cancer of the testicles.” It did accept “cancer of the breasts” and “bosom cancer” but not “cancer of the breast” or “breast cancer.” “Bosom cancer” sounds so wrong.
“Damn,” a profane word (“this word may be offensive to your reader,” my word-processing software notes), was not flagged. Obviously, that submission manager needs the college experience I was fortunate to have to discern the difference between “breast cancer” and “damn cancer.”
The game was fun, but it did not inspire me to complete my story submission. More important was an email to my alumni association to suggest that graduates be allowed to mention “breast cancer.” This seemed to be the least I could do in honor of National Breast Cancer Awareness Month. If there is a 1 in 8 chance a woman will develop breast cancer, according to the American Cancer Society, I am not the only graduate who might want to mention it.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Presurgical Opdivo, Chemo See High Response in Early-Stage Breast Cancer
December 9th 2023Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.
Read More
Consider Endocrine Therapy Responses When Planning Chemo in Breast Cancer Subset
December 9th 2023Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age.
Read More
‘The Complete Guide to Breast Reconstruction’ Author Empowers Patients With Information
October 5th 2023Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.
Listen
Kadcyla Is the ‘First Therapy to Show Improved Survival’ in a Breast Cancer Subset
December 8th 2023Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.
Read More